DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Gilotrif" drug pipelines has been added to ResearchAndMarkets.com's offering.
Gilotrif is an orally administered TKI that irreversibly binds to EGFR/human epidermal growth factor receptor 1 (HER1), HER2, and HER4.
In cancerous cells where EGFR and HER2 receptors are overexpressed, activation of these receptors can trigger cell-signaling pathways that lead to uncontrolled tumor cell proliferation. Gilotrif works by blocking these receptors, preventing their activation and thereby inhibiting the unwanted signaling pathways.
Gilotrif irreversibly binds to two key receptors involved in cell proliferation and it is thought that it will be more effective than first-generation TKIs which only provided single reversible receptor blocking (Gilotrif prescribing information, 2016; Minkovsky and Berezov, 2008).
List of Figures
Figure 1: Gilotrif for head and neck cancer - SWOT analysis
Figure 2: Drug assessment summary of Gilotrif for SCCHN
Figure 3: Drug assessment summary of Gilotrif for SCCHN
Figure 4: Gilotrif sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Figure 5: Gilotrif for non-small cell lung cancer - SWOT analysis
Figure 6: Drug assessment summary for Gilotrif in non-small cell lung cancer
Figure 7: Drug assessment summary for Gilotrif in non-small cell lung cancer
List of Tables
Table 1: Gilotrif drug profile
Table 2: Gilotrif Phase III trials in head and neck cancer
Table 3: Gilotrif Phase III trial data in head and neck cancer
Table 4: Gilotrif early-phase data in head and neck cancer
Table 5: Gilotrif sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 6: Gilotrif patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017-26
Table 7: Gilotrif drug profile
Table 8: Gilotrif pivotal trial data in non-small cell lung cancer
Table 9: Gilotrif late-phase trial data in non-small cell lung cancer
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vn8wc6/gilotrif_drug?w=4
